As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Celltrion was next to announce the availability ... Indications for which Humira’s regulatory exclusivity have already lapsed include rheumatoid arthritis, Crohn’s disease, plaque psoriasis ...

of Humira. Most are, however, working to get interchangeable status for their biosimilars, and three of them – Organon/Samsung Bioepis’ Hadlima, Sandoz’ Hyrimoz, and Celltrion’s Yuflyma ...

Tocilizumab-anoh is the seventh biosimilar by Celltrion to receive FDA approval, enhancing their treatment portfolio. Avtozma, the third biosimilar to Actemra, has received FDA approval for ...

Celltrion, a leading biopharmaceutical company based in Incheon, South Korea, announced that the US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an ...

SEOUL, Dec. 13 (Yonhap) -- South Korea's major biopharmaceutical company Celltrion Inc. said Friday it will hand out the biggest-ever cash and stock dividends to its shareholders as part of ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement between Amgen and Celltrion resolving the BPCIA ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Celltrion announced on Friday that its biosimilar Avtozma, a version of the autoimmune disease treatment Actemra (active ingredient tocilizumab), has received product approval from the US Food and ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions ...